Fate Therapeutics Inc (FATE)

01:00 AM

NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.

01:00 AM

Feb 22, 2025

Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025

Feb 20, 2025

iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World

Feb 20, 2025

Feb 20, 2025

Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Feb 20, 2025

Feb 18, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Feb 18, 2025

Feb 18, 2025

Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat

Feb 18, 2025

Feb 17, 2025

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance

Feb 17, 2025

Feb 17, 2025

Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat

Feb 17, 2025

Feb 17, 2025

FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World

Feb 17, 2025

Feb 16, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - accessnewswire.com

Feb 16, 2025

Feb 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of “Hold” from Analysts - Defense World

Feb 16, 2025

Feb 15, 2025

What is Leerink Partnrs’ Estimate for FATE Q1 Earnings? - Defense World

Feb 15, 2025

Feb 14, 2025

Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Feb 14, 2025

Feb 14, 2025

SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Feb 14, 2025

Feb 10, 2025

Navigating FATE Stock: Fate Therapeutics Inc Journey - The InvestChronicle

Feb 10, 2025

Feb 10, 2025

Analysts review Fate Therapeutics Inc’s rating - Knox Daily

Feb 10, 2025

Feb 06, 2025

CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail

Feb 06, 2025

Feb 06, 2025

Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News

Feb 06, 2025

Feb 06, 2025

Fate Therapeutics Inc (FATE) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

Feb 06, 2025

Feb 04, 2025

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap (FATE) - Seeking Alpha

Feb 04, 2025

Feb 04, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 04, 2025

Feb 04, 2025

Fate Therapeutics Inc [FATE] Investment Appeal on the Rise - Knox Daily

Feb 04, 2025

Feb 04, 2025

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate - Yahoo Finance

Feb 04, 2025

Feb 04, 2025

Fate Therapeutics Inc (FATE)’s stock performance: a year in review - US Post News

Feb 04, 2025

Feb 03, 2025

FATE 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action - ACCESS Newswire

Feb 03, 2025

Feb 03, 2025

Fate Therapeutics Inc (FATE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Feb 03, 2025

Jan 31, 2025

Fate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progress - MSN

Jan 31, 2025

Jan 28, 2025

Fate Therapeutics Inc (NASDAQ: FATE) Is A Buzzing Hot Stock - Stocks Register

Jan 28, 2025

Jan 25, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 25, 2025

Jan 23, 2025

Equities Analysts Offer Predictions for FATE FY2025 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

Research Analysts Set Expectations for FATE FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 22, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 22, 2025

Jan 19, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat

Jan 19, 2025

Jan 16, 2025

JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 16, 2025

Jan 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat

Jan 16, 2025

Jan 15, 2025

Day 0 of Loss Streak for Fate Therapeutics Stock with 0% Return (vs. -20% YTD) [1/22/2025] - Trefis

Jan 15, 2025

Jan 14, 2025

Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com

Jan 14, 2025

Jan 13, 2025

Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat

Jan 13, 2025

Jan 13, 2025

Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 13, 2025

Jan 07, 2025

Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com

Jan 07, 2025

Jan 07, 2025

Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada

Jan 07, 2025

Jan 06, 2025

Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com

Jan 06, 2025

Jan 06, 2025

Fate Therapeutics Announces Executive Leadership Transition - TipRanks

Jan 06, 2025